Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03635112 |
Recruitment Status :
Terminated
(The decision was made following the planned review of trial data by the independent data monitoring committee who determined that, while there are no safety concerns, there are concerns about the ongoing benefit-risk of continuing the trial.)
First Posted : August 17, 2018
Last Update Posted : January 27, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Crohn's Disease | Drug: Placebo Drug: TD-1473 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 167 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease |
Actual Study Start Date : | November 19, 2018 |
Actual Primary Completion Date : | December 30, 2021 |
Actual Study Completion Date : | December 30, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Active Treatment TD-1473 with Dose A
1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks. |
Drug: TD-1473
TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period. |
Active Comparator: Active Treatment TD-1473 with Dose B
1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks. |
Drug: TD-1473
TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period. |
Placebo Comparator: Placebo
1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks. |
Drug: Placebo
Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. Drug: TD-1473 TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period. |
- Improvement in Crohn's Disease Activity Index (CDAI) score from Baseline to Week 12 (PRIMARY) [ Time Frame: 12 weeks ]
To assess the effect of TD-1473 compared to placebo in improving Crohn's Disease Activity Index (CDAI) score at week 12 in subjects with moderately to severely active CD.
The CDAI score is generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Patients will report information regarding symptoms using a diary.
- Clinical response measured by CDAI [ Time Frame: 12 weeks ]To assess the effects of TD-1473 given for 12 weeks compared to placebo. CDAI clinical response is determined by a CDAI score decreasing from baseline to Week 12 by a defined value or CDAI below a defined value by Week 12. Crohn's Disease Activity Index also known as CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease.
- CDAI clinical remission [ Time Frame: 12 weeks ]To assess the effects of TD-1473 given for 12 weeks compared to placebo. CDAI clinical remission is determined by a CDAI score being less than a defined value at Week 12. Crohn's Disease Activity Index also known as CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease.
- SES-CD (Simple Endoscopic Score for Crohn's Disease) change from baseline to Week 12 [ Time Frame: 12 weeks ]
To assess the effects of TD-1473 given for 12 weeks compared to placebo. Simple Endoscopic Score for Crohn's Disease also known as SES-CD provides a quantitative assessment of Crohn's Disease across all 5 bowel segments and allow for comparison across populations and within an individual over time.
The SES-CD incorporates 4 descriptors: the ulcer size, the proportion of surface covered by ulcer, the proportion of surface covered by other lesions, and the presence of stenosis. Each descriptor is graded from 0-3 and is scored in 5 segments (ileum, right colon, transverse colon, left colon, and rectum). The total score is calculated as the sum of all the items in each segment and can range from 0 to 60.
- Endoscopic response [ Time Frame: 12 weeks ]
To assess the effects of TD-1473 given for 12 weeks compared to placebo. Endoscopic Response is determined by a reduction of SES-CD (Simple Endoscopic Score for Crohn's Disease is also known as SES-CD) score or Endoscopic Remission at Week 12.
Simple Endoscopic Score for Crohn's Disease also known as SES-CD provides a quantitative assessment of Crohn's Disease across all 5 bowel segments and allow for comparison across populations and within an individual over time.
The SES-CD incorporates 4 descriptors: the ulcer size, the proportion of surface covered by ulcer, the proportion of surface covered by other lesions, and the presence of stenosis. Each descriptor is graded from 0-3 and is scored in 5 segments (ileum, right colon, transverse colon, left colon, and rectum). The total score is calculated as the sum of all the items in each segment and can range from 0 to 60.
- Stool Frequency and Abdominal Pain (SFAP) clinical remission [ Time Frame: 12 weeks ]To assess the effects of TD-1473 given for 12 weeks compared to placebo. Stool Frequency and Abdominal Pain (SFAP) clinical remission is determined using a patient reported Abdominal Pain score [which uses a scale of 0 - 3 with 0 representing 'no pain' and 3 representing 'severe pain'] and patient reported Stool Frequency.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Is at least 18 years of age at screening
- Males and females with clinical evidence of Crohn's disease for at least 3 months duration at screening
- Moderately-to-severely active Crohn's Disease at baseline, as defined by a Crohn's Disease Activity Index (CDAI) score of 220-450 inclusive
- SES-CD score of ≥ 3 with ulceration (corresponding to a score of 1) in at least 1 of the 5 ileocolonic segments on the Ulcerated Surface subscore of the SES-CD]
- Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to conventional therapy (aminosalicylates, corticosteroids and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate) or biologics (e.g., anti-TNF therapy, anti-IL-12/23 (anti-interleukin), anti-integrin).
- Additional inclusion criteria apply
Exclusion Criteria:
- Is currently receiving biologic (anti-TNF, anti-integrin, or anti-IL12/23) therapy
- Has a current bacterial, parasitic, fungal, or viral infection
- Has clinically significant abnormalities in laboratory evaluations
- Prior exposure or potential exposure to a JAK inhibitor that was stopped due to intolerance or lack of efficacy
- Subject has participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to Screening or 5x the half-life of the investigational drug, whichever is longer, or is currently participating in another trial of an investigational drug (or medical device)
- Subject has failed ≥ 3 biologic agents of 3 different mechanisms of action (i.e., anti-TNF, anti-integrin, and anti-IL12/23)
- Additional exclusion criteria apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03635112

Study Director: | Medical Monitor | Theravance Biopharma |
Responsible Party: | Theravance Biopharma |
ClinicalTrials.gov Identifier: | NCT03635112 |
Other Study ID Numbers: |
0173 2018-001272-37 ( EudraCT Number ) |
First Posted: | August 17, 2018 Key Record Dates |
Last Update Posted: | January 27, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
TD-1473 Janus kinase inhibitor JAK inhibitor Inflammatory Bowel Disease |
IBD Crohn's Disease Intestinal restriction |
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis |
Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |